Treatment with 102-5 anti-CLPTM1L significantly lowered cisplatin IC50s in HeyA8-CisR (11.2 μM, 95% confidence interval [CI] 8.3–15.8 vs. 5.9 μM [CI] 3.7–9.3, p = 0.0056), OVCAR5-CisR (8.8 μM [CI] 6.6–11.85 vs. 3.4 [CI] 2.2–5.7, p = 5.5 × 10−5) and PeO4 (6.0 μM [CI] 4.2–8.6 vs. 2.9 [CI] 1.7–4.9, p = 4.2 × 10−5) cisplatin-resistant HGSOC and ovarian cystadenocarcinoma cell lines (Fig. 2b). Here, CLPTM1L is linked to ovarian cystadenocarcinoma.